Investigations into peripheral immunity in ASD generally reveal an inflammatory profile, with IL-17A and IL-16 (and, in some cases, IL-9) representing key mediators reported to differ from controls 2,3,9,10,11
Hypoglycemia can occur, particularly when tirzepatide is used in combination with insulin or sulfonylureas, though it is uncommon when used as monotherapy due to the glucose-dependent mechanism of insulin secretion
POPs (persistent organic pollutants) are xenobiotics
It's up to you to decide Imbms you want to use and which ones you don't want
Additionally, overexpression of CHAC1 can enhance the sensitivity of tumor cells to chemotherapy by reducing intracellular GSH levels, thereby increasing oxidative stress and promoting cell death
Yoon CH